Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 10.97
+0.06 (0.55%)
Jul 6, 2026, 9:49 AM EST
Satellos Bioscience Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
227.27M CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSatellos Bioscience News
- 6 days ago - Satellos' SAT-3247 Wins FDA Fast Track Status For Duchenne Muscular Dystrophy, Stock Up - Nasdaq
- 7 days ago - Satellos Bioscience's Duchenne Drug SAT-3247 Wins FDA Fast Track Designation - Nasdaq
- 7 days ago - Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 10 days ago - Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? - Nasdaq
- 11 days ago - Satellos to Present Clinical Program Updates at ICNMD 2026 - GlobeNewsWire
- 18 days ago - Satellos Bioscience Announces Results of Annual Meeting of Shareholders - GlobeNewsWire
- 4 weeks ago - Satellos Bioscience Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Satellos Bioscience Annual report - Filings